Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-Current Assets (2019 - 2025)

Revolution Medicines has reported Non-Current Assets over the past 7 years, most recently at $279.5 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $279.5 million for Q4 2025, up 21.16% from a year ago — trailing twelve months through Dec 2025 was $1.0 billion (up 33.5% YoY), and the annual figure for FY2025 was $279.5 million, up 21.16%.
  • Non-Current Assets for Q4 2025 was $279.5 million at Revolution Medicines, up from $274.4 million in the prior quarter.
  • Over the last five years, Non-Current Assets for RVMD hit a ceiling of $279.5 million in Q4 2025 and a floor of $111.4 million in Q3 2021.
  • Median Non-Current Assets over the past 5 years was $155.8 million (2022), compared with a mean of $177.4 million.
  • Biggest five-year swings in Non-Current Assets: decreased 0.65% in 2021 and later surged 49.26% in 2025.
  • Revolution Medicines' Non-Current Assets stood at $148.2 million in 2021, then increased by 2.38% to $151.7 million in 2022, then rose by 20.22% to $182.4 million in 2023, then increased by 26.45% to $230.7 million in 2024, then grew by 21.16% to $279.5 million in 2025.
  • The last three reported values for Non-Current Assets were $279.5 million (Q4 2025), $274.4 million (Q3 2025), and $253.1 million (Q2 2025) per Business Quant data.